Key clinical point : Rheumatic immune-related adverse events occurred in approximately one-third of cancer patients on immune checkpoint inhibitor (ICI) therapy.
Major finding: A total of 37.3% of patients on ICI therapy experienced at least one immune-related adverse event; 4.3% of patients experienced at least one rheumatic immune-related adverse event (rh-irAEs) and 3 of these patients had pre-existing rheumatic disease.
Study details: The data come from 437 adult cancer patients who were treated with ipilimumab and/or nivolumab, or pembrolizumab at a single center between January 2014 and December 2018.
Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.
Source: Verspohl SH et al. Ther Adv Musculoskelet Dis. 2021 Apr 12 . doi: 10.1177/1759720X211006963.